# US 2010/0166745 A1 · Transferrin receptor antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166745 A1
- Document ID: US20100166745A1
- Status: Published application
- Kind: A1
- Application number: 12/483,774
- Filed: 2009-06-12
- Published: 2010-07-01
- Earliest claimed: 2004-06-07
- Assignees: MacroGenics, Inc.
- Inventors: Jennie P. MATHER; Penelope E. Roberts; Ronghao Li
- Web page: https://patentgrep.com/patent/US20100166745A1

## CPC

- C07K 16/2881: {against CD71}
- A61K 39/39533: {against materials from animals}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/77: Internalization into the cell
- Y10S 530/808: Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S 530/809: Fused cells, e.g. hybridoma
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention provides further characterization of the disease and cancer-associated antigen, transferrin receptor. The invention also provides a novel family of antibodies that bind to the transferrin receptor, methods of diagnosing and treating various human cancers and diseases that express transferrin receptor.

## Claims

### Claim at position 1

1-17. (canceled)

### Claim 18

A method for delivering a chemotherapeutic agent to a cancer cell comprising administering a composition comprising an antibody that is capable of binding to the LUCA31 epitope, associated with the chemotherapeutic agent, wherein the cancer cell is selected from the group consisting of cancer cells from adrenal gland tumors, AIDS-associated cancers, alveolar soft part sarcoma, astrocytic tumors, bladder cancer (squamous cell carcinoma and transitional cell carcinoma), bone cancer (adamantinoma, aneurysmal bone cysts, osteochondroma, osteosarcoma), brain and spinal cord cancers, metastatic brain tumors, breast cancer, carotid body tumors, cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, cutaneous benign fibrous histiocytomas, desmoplastic small round cell tumors, ependymomas, Ewing's tumors, extraskeletal myxoid chondrosarcoma, fibrogenesis imperfecta ossium, fibrous dysplasia of the bone, gallbladder and bile duct cancers, gestational trophoblastic disease, germ cell tumors, head and neck cancers, islet cell tumors, Kaposi's sarcoma, kidney cancer (nephroblastoma, papillary renal cell carcinoma), leukemias, lipoma/benign lipomatous tumors, liposarcoma/malignant lipomatous tumors, liver cancer (hepatoblastoma, hepatocellular carcinoma), lymphomas, lung cancer, medulloblastoma, melanoma, meningiomas, multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, neuroendocrine tumors, ovarian cancer, pancreatic cancers, papillary thyroid carcinomas, parathyroid tumors, pediatric cancers, peripheral nerve sheath tumors, phaeochromocytoma, pituitary tumors, prostate cancer, uveal or intraocular melanoma, rare hematologic disorders, renal metastatic cancer, rhabdoid tumor, rhabdomysarcoma, sarcomas, skin cancer, soft-tissue sarcomas, squamous cell cancer, stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid metastatic cancer, and uterine cancers (carcinoma of the cervix, endometrial carcinoma, and leiomyoma).

### Claim 19 (depends on 18)

The method of claim 18, wherein the chemotherapeutic agent is administered to an individual.

### Claim 20 (depends on 18)

The method of claim 18, wherein the antibody is an antibody expressed by hybridoma ATCC No. PTA-6055 or progeny thereof.

### Claim 21

A method of inhibiting growth of cancer cells in an individual comprising administering to the individual an effective amount of a composition comprising an anti-transferrin receptor antibody capable of binding to the LUCA31 epitope associated with a chemotherapeutic agent to the individual, wherein the cancer cells are selected from the group consisting of cancer cells from adrenal gland tumors, AIDS-associated cancers, alveolar soft part sarcoma, astrocytic tumors, bladder cancer (squamous cell carcinoma and transitional cell carcinoma), bone cancer (adamantinoma, aneurysmal bone cysts, osteochondroma, osteosarcoma), brain and spinal cord cancers, metastatic brain tumors, breast cancer, carotid body tumors, cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, cutaneous benign fibrous histiocytomas, desmoplastic small round cell tumors, ependymomas, Ewing's tumors, extraskeletal myxoid chondrosarcoma, fibrogenesis imperfecta ossium, fibrous dysplasia of the bone, gallbladder and bile duct cancers, gestational trophoblastic disease, germ cell tumors, head and neck cancers, islet cell tumors, Kaposi's sarcoma, kidney cancer (nephroblastoma, papillary renal cell carcinoma), leukemias, lipoma/benign lipomatous tumors, liposarcoma/malignant lipomatous tumors, liver cancer (hepatoblastoma, hepatocellular carcinoma), lymphomas, lung cancer, medulloblastoma, melanoma, meningiomas, multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, neuroendocrine tumors, ovarian cancer, pancreatic cancers, papillary thyroid carcinomas, parathyroid tumors, pediatric cancers, peripheral nerve sheath tumors, phaeochromocytoma, pituitary tumors, prostate cancer, uveal or intraocular melanoma, rare hematologic disorders, renal metastatic cancer, rhabdoid tumor, rhabdomysarcoma, sarcomas, skin cancer, soft-tissue sarcomas, squamous cell cancer, stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid metastatic cancer, and uterine cancers (carcinoma of the cervix, endometrial carcinoma, and leiomyoma).

### Claim 22 (depends on 21)

The method of claim 21, wherein the chemotherapeutic agent is delivered into the cancer cells.

### Claim 23 (depends on 21)

The method of claim 21, wherein the antibody is expressed by hybridoma ATCC No. PTA-6055 or progeny thereof.

### Claim at position 8

24-27. (canceled)

### Claim 28

A method of inhibiting growth of cancer cells in an individual, comprising administering to the individual an effective amount of a composition comprising an antibody capable of binding to the LUCA31 epitope of the human transferrin receptor, wherein the cancer cells are selected from the group consisting of cancer cells from adrenal gland tumors, AIDS-associated cancers, alveolar soft part sarcoma, astrocytic tumors, bladder cancer (squamous cell carcinoma and transitional cell carcinoma), bone cancer (adamantinoma, aneurysmal bone cysts, osteochondroma, osteosarcoma), brain and spinal cord cancers, metastatic brain tumors, breast cancer, carotid body tumors, cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, cutaneous benign fibrous histiocytomas, desmoplastic small round cell tumors, ependymomas, Ewing's tumors, extraskeletal myxoid chondrosarcoma, fibrogenesis imperfecta ossium, fibrous dysplasia of the bone, gallbladder and bile duct cancers, gestational trophoblastic disease, germ cell tumors, head and neck cancers, islet cell tumors, Kaposi's sarcoma, kidney cancer (nephroblastoma, papillary renal cell carcinoma), leukemias, lipoma/benign lipomatous tumors, liposarcoma/malignant lipomatous tumors, liver cancer (hepatoblastoma, hepatocellular carcinoma), lymphomas, lung cancer, medulloblastoma, melanoma, meningiomas, multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, neuroendocrine tumors, ovarian cancer, pancreatic cancers, papillary thyroid carcinomas, parathyroid tumors, pediatric cancers, peripheral nerve sheath tumors, phaeochromocytoma, pituitary tumors, prostate cancer, uveal or intraocular melanoma, rare hematologic disorders, renal metastatic cancer, rhabdoid tumor, rhabdomysarcoma, sarcomas, skin cancer, soft-tissue sarcomas, squamous cell cancer, stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid metastatic cancer, and uterine cancers (carcinoma of the cervix, endometrial carcinoma, and leiomyoma).

### Claim 29 (depends on 28)

The method of claim 28, wherein the antibody is expressed by hybridoma ATCC No. PTA-6055 or progeny thereof.

### Claim 30 (depends on 28)

The method of claim 28, wherein the antibody comprises an antigen-binding fragment of the antibody expressed by hybridoma ATCC No. PTA-6055 or progeny thereof.

### Claim 31 (depends on 28)

The method of claim 28, wherein the antibody comprises at least one complementarity determining region of the antibody expressed by hybridoma ATCC No. PTA-6055 or progeny thereof.

### Claim at position 13

32-35. (canceled)

### Claim 36 (depends on 18)

The method of claim 18, wherein the antibody comprises an antigen-binding fragment of the antibody expressed by the hybridoma ATCC No. PTA-6055 or progeny thereof.

### Claim 37 (depends on 18)

The method of claim 18, wherein the antibody comprises the three complementarity determining regions from the light chain and the three complementarity determining regions from the heavy chain of antibody LUCA31 expressed by the hybridoma having ATCC No. PTA-6055 or progeny thereof.

### Claim 38 (depends on 37)

The method of claim 37, wherein the antibody comprises is a chimeric antibody.

### Claim 39 (depends on 37)

The method of claim 37, wherein the antibody is a humanized antibody.

### Claim 40 (depends on 37)

The method of claim 37, wherein the antibody is a chimeric antibody comprising the heavy chain and the light chain variable region sequences from antibody LUCA31 produced by the cell line having ATCC No. PTA-6055 or progeny thereof.

### Claim 41 (depends on 40)

The method of claim 40, wherein the antibody comprises the heavy chain constant region sequence and the light chain constant region sequence from a human antibody.

### Claim 42 (depends on 18)

The method of claim 18, wherein the antibody comprises the heavy chain variable region sequence from antibody LUCA31 produced by the cell line having ATCC No. PTA-6055 or progeny thereof.

### Claim 43 (depends on 18)

The method of claim 18, wherein the antibody comprises the light chain variable region sequence from antibody LUCA31 produced by the cell line having ATCC No. PTA-6055 or progeny thereof.

### Claim 44 (depends on 37)

The method of claim 37, wherein the antibody comprises an antigen-binding fragment; wherein the antigen-binding fragment is selected from the group consisting of a Fab, a Fab′, a F(ab′)2 and a Fv; and wherein the antigen-binding fragment retains the binding specificity of antibody LUCA31 produced by the cell line having ATCC No. PTA-6055 or progeny thereof.

### Claim 45 (depends on 21)

The method of claim 21, wherein the antibody comprises an antigen-binding fragment of the antibody expressed by the hybridoma ATCC No. PTA-6055 or progeny thereof.

### Claim 46 (depends on 21)

The method of claim 21, wherein the antibody comprises the three complementarity determining regions from the light chain and the three complementarity determining regions from the heavy chain of antibody LUCA31 expressed by the hybridoma having ATCC No. PTA-6055 or progeny thereof.

### Claim 47 (depends on 46)

The method of claim 46, wherein the antibody comprises is a chimeric antibody.

### Claim 48 (depends on 46)

The method of claim 46, wherein the antibody is a humanized antibody.

### Claim 49 (depends on 46)

The method of claim 46, wherein the antibody is a chimeric antibody comprising the heavy chain and the light chain variable region sequences from antibody LUCA31 produced by the cell line having ATCC No. PTA-6055 or progeny thereof.

### Claim 50 (depends on 49)

The method of claim 49, wherein the antibody comprises the heavy chain constant region sequence and the light chain constant region sequence from a human antibody.

### Claim 51 (depends on 21)

The method of claim 21, wherein the antibody comprises the heavy chain variable region sequence from antibody LUCA31 produced by the cell line having ATCC No. PTA-6055 or progeny thereof.

### Claim 52 (depends on 21)

The method of claim 21, wherein the antibody comprises the light chain variable region sequence from antibody LUCA31 produced by the cell line having ATCC No. PTA-6055 or progeny thereof.

### Claim 53 (depends on 46)

The method of claim 46, wherein the antibody comprises an antigen-binding fragment; wherein the antigen-binding fragment is selected from the group consisting of a Fab, a Fab′, a F(ab′)2 and a Fv; and wherein the antigen-binding fragment retains the binding specificity of antibody LUCA31 produced by the cell line having ATCC No. PTA-6055 or progeny thereof.

### Claim 54 (depends on 28)

The method of claim 28, wherein the antibody comprises the three complementarity determining regions from the light chain and the three complementarity determining regions from the heavy chain of antibody LUCA31 expressed by the hybridoma having ATCC No. PTA-6055 or progeny thereof.

### Claim 55 (depends on 54)

The method of claim 54, wherein the antibody comprises is a chimeric antibody.

### Claim 56 (depends on 54)

The method of claim 54, wherein the antibody is a humanized antibody.

### Claim 57 (depends on 54)

The method of claim 54, wherein the antibody is a chimeric antibody comprising the heavy chain and the light chain variable region sequences from antibody LUCA31 produced by the cell line having ATCC No. PTA-6055 or progeny thereof.

### Claim 58 (depends on 57)

The method of claim 57, wherein the antibody comprises the heavy chain constant region sequence and the light chain constant region sequence from a human antibody.

### Claim 59 (depends on 28)

The method of claim 28, wherein the antibody comprises the heavy chain variable region sequence from antibody LUCA31 produced by the cell line having ATCC No. PTA-6055 or progeny thereof.

### Claim 60 (depends on 28)

The method of claim 28, wherein the antibody comprises the light chain variable region sequence from antibody LUCA31 produced by the cell line having ATCC No. PTA-6055 or progeny thereof.

### Claim 61 (depends on 54)

The method of claim 54, wherein the antibody comprises an antigen-binding fragment; wherein the antigen-binding fragment is selected from the group consisting of a Fab, a Fab′, a F(ab′)2 and a Fv; and wherein the antigen-binding fragment retains the binding specificity of antibody LUCA31 produced by the cell line having ATCC No. PTA-6055 or progeny thereof.
